Jacobio Pharma Announces 2023 Interim Results

BEIJING, SHANGHAI and BOSTON, Aug. 30, 2023 /PRNewswire/ — Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, announced its 2023 interim results. During the period, the company recorded revenue of RMB 40.3 million even as it continued to…